The Intellectual Property Committee of the Transatlantic Consumer Dialogue (TACD) has adopted a new resolution on access to medicines.
In the European Union and in the United States the cost of medicines is creating a growing financial burden for patients and health systems. TACD calls for new and fair incentives for biomedical innovation that promote the right to access, the sharing of medical knowledge and the protection of public health. Based on existing TACD policy resolutions, specific recommendations for new models of biomedical innovation are made to policymakers on both sides of the Atlantic. In particular, policies that de-link Research and Development (R&D) costs from the marketing price of new, useful and safe medicines should be pursued.